| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $29K | +13.9% | +27.3% |
| Cost of Revenue | $5K | +58.6% | +344.3% |
| R&D Expense | $2.9M | +10.4% | -23.8% |
| SG&A Expense | $2.3M | -23.3% | +53.7% |
| Operating Income | -$5.2M | +7.6% | +2.2% |
| Income Tax | $0 | — | — |
| Net Income | -$5.1M |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $34.9M | +58.1% | +30.0% |
| Accounts Receivable | $36K | +232.5% | +33.3% |
| Current Assets | $35.5M | +55.8% | +29.1% |
| Total Assets | $44.8M | +38.1% | +20.3% |
| Current Liabilities | $1.1M | +4.0% | +1.7% |
| Total Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$10.4M | — | — |
| Capital Expenditures | $953K | — | — |
| Investing Cash Flow | -$1.2M | — | — |
| Financing Cash Flow | $18.9M | — | — |
| Free Cash Flow | -$11.4M | — | — |
| +3.8% |
| EPS (Basic) | -$0.04 | +20.0% | +0.0% |
| EPS (Diluted) | -$0.04 | +20.0% | +0.0% |
| $3.6M |
| -0.2% |
| -4.5% |
| Stockholders' Equity | $41.2M | +42.9% | +23.1% |